Although these experiments were, in fact, designed to evaluate this possibility, our original working hypothesis was based conceptually on well-established effects of E-cadherin downregulation in cancer (i.e., increased cell motility, epithelial-mesenchymal transition, invasiveness and/or reduced contact inhibition of cell growth). The gene discussed is CDH1; the disease is cancer.